Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5XH2C)

Drug Name

Methotrexate Sodium Drug Info

Synonyms

Methotrexate disodium salt; 7413-34-5; Sodium methotrexate; MTX disodium; methotrexate disodium; UNII-3IG1E710ZN; 3IG1E710ZN; CHEBI:50679; Amethopterin sodium; Disodium methotrexate; Methotrexat dinatrium; Mexate-Aq Preserved; Methotrexate sodium salt; EINECS 231-022-0; 59-05-2 (Parent); Methotrexate Preservative Free; 4-Amino-N(sup 10)-methylpteroylglutamic acid disodium salt; METHOTREXATE SODIUM PRESERVATIVE FREE

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Approved	[1]

Therapeutic Class

Anticancer Agents

Cross-matching ID

PubChem CID: 11329481
ChEBI ID: CHEBI:50679
CAS Number: CAS 7413-34-5
TTD Drug ID: DM5XH2C

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Dihydrofolate reductase (DHFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trimethoprim	DMM7CHK	Acute otitis media	AB00	Approved	[2]
Aminosalicylic Acid	DMENSL5	Crohn disease	DD70	Approved	[2]
Leucovorin Calcium	DMNWZJG	Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Iclaprim	DM7YNV9	Bacterial infection	1A00-1C4Z	Phase 3	[4]
PIRITREXIM	DM276N1	Bladder cancer	2C94	Phase 2	[5]
CH-4051	DMLQRYH	Rheumatoid arthritis	FA20	Phase 2	[6]
MDAM (y-methylene-10-deazaaminopterin)	DM1DISM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
L-MDAM	DMU901D	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
VYR 006	DMC9N7D	Toxoplasmosis	1F57	Phase 1	[9]
TNP-351	DMW05DS	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dihydrofolate reductase (DHFR)	TTYZVDJ	DYR_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3	Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.NCI Monogr.1987;(5):17-26.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Structural variations of piritrexim, a lipophilic inhibitor of human dihydrofolate reductase: synthesis, antitumor activity and molecular modeling ... Eur J Med Chem. 2004 Dec;39(12):1079-88.
6	CH-1504, a metabolically inert antifolate for the potential treatment of rheumatoid arthritis. IDrugs. 2010 Aug;13(8):559-67.
7	Evaluation of the importance of hydrophobic interactions in drug binding to dihydrofolate reductase. J Med Chem. 1988 Jan;31(1):129-37.
8	Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity. Clin Cancer Res. 1996 Apr;2(4):707-12.
9	Clinical pipeline report, company report or official report of Vyera Pharmaceuticals.
10	A Ring-Transformation/Ring-Annulation Strategy for the Synthesis of the DHFR Inhibitor, TNP-351: A Correction. J Org Chem. 1996 Nov 1;61(22):7973-7974.